Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    xyz-pharma-2025-04-21

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Menu

    Fremanezumab

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Teva's Ajovy FDA filing accepted for pediatric migraine prevention
    Teva's Ajovy FDA filing accepted for pediatric migraine prevention

    07 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/07/3056596/0/en/Teva-Announces-FDA-Filing-Acceptance-for-AJOVY-fremanezumab-in-Pediatric-Episodic-Migraine-Prevention.html

    GLOBENEWSWIRE
    07 Apr 2025
    Share Share
    Teva Presents Positive Ph 3 Trial Data for AJOVY® in Children
    Teva Presents Positive Ph 3 Trial Data for AJOVY® in Children

    04 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/04/2991203/0/en/Teva-Presents-Positive-Efficacy-and-Safety-Data-of-AJOVY-fremanezumab-for-the-Prevention-of-Episodic-Migraine-in-Children-and-Adolescents-from-Phase-3-SPACE-Trial.html

    GLOBENEWSWIRE
    04 Dec 2024
    Share Share
    Teva touts first CGRP success in Phase III paediatric migraine prevention study
    Teva touts first CGRP success in Phase III paediatric migraine prevention study

    19 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240718183120/en/Teva-Announces-First-Phase-3-Evidence-of-Efficacy-and-Safety-of-an-Anti-CGRP-Monoclonal-Antibody-in-Children-in-AJOVY%C2%AE-fremanezumab-SPACE-Trial-for-Prevention-of-Episodic-Migraine

    BUSINESSWIRE
    19 Jul 2024
    Share Share
    Teva's AJOVY® Effective, Safe For Migraine Prevention In China
    Teva's AJOVY® Effective, Safe For Migraine Prevention In China

    11 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240411323269/en

    BUSINESSWIRE
    11 Apr 2024
    Share Share
    New Post Hoc Phase 3 Data Analysis Shows AJOVYReduced Migraine Attacks
    New Post Hoc Phase 3 Data Analysis Shows AJOVYReduced Migraine Attacks

    06 Dec 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231205617527/en

    BUSINESSWIRE
    06 Dec 2023
    Share Share
    Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks
    Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks

    17 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231016121295/en

    BUSINESSWIRE
    17 Oct 2023
    Share Share